The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: A case-control study and meta-analysis

Journal of the Neurological Sciences

Volumn 153, Issue 1, 1997, Pages 50-53

  McCann, S J ^a   Pond, S M ^a   James, K M ^a   Le Couteur, D G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cytochrome P450 2D6; Debrisoquine hydroxylase; Genetics; Meta analysis; Parkinson's disease; Polymorphism

Indexed keywords

CYTOCHROME P450; NEUROTOXIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; FEMALE; GENOTYPE; HUMANS; MALE; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 0031472072     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00179-2     Document Type: Article

References (25)

1. Agundez J.A., Jiminez-Jiminez F.J., Luengo A., Bernal M.L., Molina J.A., Ayuso L., Vazquez A., Parra J., Duarte J., Coria F., Ladero J.M., Alvarez J.C., Benitez J. Association between the oxidative polymorphism and early onset Parkinson's disease. Clin. Pharmacol. Ther. 57:1995;291-298.
2. Akhmedova S.N., Pushnova E.A., Yakimovsky A.F., Avtonomov V.V., Schwartz E.I. Frequency of a specific cytochrome P4502D6B (CYP2D6B) mutant allele in clinically differentiated groups of patients with Parkinson disease. Biochem. Mol. Med. 54:1995;88-90.
3. Armstrong M., Daly A.K., Cholerton S., Bateman D.N., Idle J.R. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 339:1992;1017-1018.
4. Barbeau A., Cloutier T., Roy M., Plasse L., Paris S., Poirer J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet. ii:1985;1213-1216.
5. Bordet R., Broly F., Destee A., Libersa C., Lafitte J.J. Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease. Clin. Neuropharmacol. 19:1996;213-221.
6. Calne D.B., Snow B.J., Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 32:1992;S125-S127.
7. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., Tucker G.T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-Demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277:1996;685-690.
8. Diederich N., Hilger C., Goetz C.G., Keipes M., Hentges F., Vieregge P., Metz H. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann. Neurol. 40:1996;463-465.
9. Gasser T., Muller-Myhsok B., Supala A., Zimmer E., Wieditz G., Wsolek Z.K., Vieregge P., Bonifati V., Oertel W.H. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 61:1996;518-520.
10. Jimenez-Jimenez F.J., Tabernero C., Mena M.A., Garcia-de-Yebenes J., Garcia-de-Yebenes M.J., Casarejos M.J., Pardo B., Garcia-Agundez J.A., Benitez J., Martinez A.et al. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metaboliser of debrisoquine. J. Neurochem. 57(1):1991;81-87.
11. Kallio J., Marttila R.J., Rinne U.K., Sonninen V., Syvalahti E. Debrisoquine oxidation in Parkinson's disease. Acta Neurol. Scand. 83:1991;194-197.
12. Kondo K., Kanazawa I. Debrisoquine hydroxylase and Parkinson's disease. Adv. Neurol. 60:1993;338-342.
13. Kurth M.C., Kurth J.H. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am. J. Med. Genet. 48:1993;166-168.
14. Le Couteur, D.G., Leighton, P.W., McCann, S.J., Pond S.M., 1997. Association of a polymorphism in the dopamine transporter gene with Parkinson's disease. Mov Disord. in press.
15. Lucotte G., Turpin J.C., Gerard N., Panserat S., Krishnamoorthy R. Mutation frequencies of the Cytochrome CYP2D6 Gene in Parkinson disease patients and in families. Am. J. Med. Genet. 67:1996;361-365.
16. Niznik H.B., Tyndale T.F., Sallee F.R., Gonzalez F.J., Hardwick J.P., Inaba T., Kalow W. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H] GBR- 12935 binding proteins. Arch. Biochem. Biophys. 276:1990;424-432.
17. Ohta S., Tachikawa O., Makino Y., Tasaki Y., Hirobe M. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ): a possible parkinsonism inducing substance in an animal model of a poor debrisquine metabolizer. Life Sci. 46:1990;599-605.
18. Plante-Bordeneuve V., Maraganore D.M., Marsden C.D., Harding A.E. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;911-913.
19. Sandy M.S., Armstrong M., Tanner C.M., Daly A.K., Di Monte D.A., Langston J.W., Idle J.R. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology. 47:1996;225-230.
20. Smith A.D., Gough A.C., Leigh P.N., Summers B.A., Harding A.E., Maranganore D.M., Sturman S.G., Schapira A.H.V., Williams A.C., Spurr N.K., Wolf C.R. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 339:1992;1375-1377.
21. Spurr N.K., Gough A.C., Smith C.A.D., Wolf C.R. Genetic analysis of the cytochrome P-450 system. Methods Enzymol. 206:1991;149-167.
22. Steiger M.J., Lledo P., Quinn N.P., Marsden C.D., Turner P., Jenner P.G. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol. Scand. 86:1992;159-164.
23. Tanner C.M. Epidemiology of Parkinson's disease. Neurol. Clin. 10:1992;317-329.
24. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61:1993;1191-1206.
25. Tsuneoka Y., Matsuo Y., Iwahashi K., Takeuchi H., Ichikawa Y.A. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J. Biochem. 114:1993;263-266.